IMV IMV Inc

IMV Inc. to Present at Upcoming Investor Conferences

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that will present at the following investor conferences in May:

RBC Capital Markets Global Healthcare Conference

  • Date: Tuesday, May 21, 2019
  • Time: 1:35 p.m. ET
  • Location: The InterContinental New York Barclay Hotel, New York, NY

National Bank Financials’ 9th Annual Quebec Conference

  • Date: Wednesday, May 29, 2019
  • Time: 9:50 a.m. ET
  • Location: Museum Room, Shangri-la Hotel, Toronto, Ontario

China Bio-Partnering Forum

  • Date: Thursday, May 30, 2019
  • Time: 1:40 p.m. CT
  • Location: Renaissance Schaumburg Convention Center Hotel, Chicago, IL

A copy of each meeting’s presentation will be available in the . A live webcast of IMV’s presentation at the RBC Capital Markets conference will also be available and archived for 90 days on the webpage.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at .

EN
14/05/2019

Underlying

IMVIMV Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMV Inc

 PRESS RELEASE
Free
IMV IMV INC

IMV Announces Closing of US$9 Million Registered Direct Offering Price...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today the closing of its previously announced registered direct offering (the “Offering”) for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each, a “Share” and, collectively, the “Shares”) and warrants to purchase up to an aggregate of 3,448,276 c...

December 20, 2022 1 EN
 PRESS RELEASE
Free
IMV IMV INC

IMV Announces US$9 Million Registered Direct Offering Priced At-The-Ma...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today that it has entered into definitive agreements for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each, a “Share” and, collectively, the “Shares”) and warrants to purchase up to an aggregate of 3,448,276 common shares (each, a “Warrant” and, ...

December 16, 2022 1 EN
 PRESS RELEASE
Free
IMV IMV INC

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Tri...

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment. Detailed results w...

December 15, 2022 1 EN
 PRESS RELEASE
Free
IMV IMV INC

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares commence trading post consolidation today. As announced and previously approved by shareholders on December 7, 2022, the Corporation has consolidated its outstanding common shares on the basis of one new common share for every 10 outstanding common shares. The consolidatio...

December 13, 2022 1 EN
 PRESS RELEASE
Free
IMV IMV INC

IMV Shareholders Approve Reverse Stock Split at 88%

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that at the special meeting of shareholders held on December 7, 2022, the share consolidation as described in the management information circular filed on October 28, 2022 (the “Circular”) was approved by the shareholders at 87.87% of the shares voted and that its board of directors has approved a 1...

December 7, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch